A 60-year-old man was admitted to the hospital with productive cough and yellowish sputum, severe fatigue, and weight loss of 4 kg over the past month; furthermore, he reported a slowly progressive shortness of breath on exertion over the past 6 months. Before admission, he received ampicillin/sulbactam (750 mg) orally twice daily for 7 days without significant clinical improvement.
On physical examination, digital clubbing was noticeable and lung auscultation revealed fine crackles on the left side of the chest anteriorly in the infraclavicular area with moderate ubiquitous wheezing. Further physical examination was normal. Basic laboratory testing showed a slightly elevated C-reactive protein with 8 mg/ dL (reference value, <0.3 mg/dL). All other laboratory values were within the normal range. Pulmonary function test revealed a total lung capacity of 5.0 L (69%), an FVC of 2.0 L (41%), an FEV 1 of 1.3 L (35%), and a FEV 1 /FVC ratio of 64%, indicating a severe obstructive airway disease with an additional restrictive defect.
Chest radiograph showed an increase in overall lung markings with diffuse bronchial wall thickening, localized opacities in the left middle and upper field, and moderate to severe emphysema (Fig 1) . Because of a possible diagnosis of TB reactivation, the patient was isolated and sputum samples were collected, but repeated smears for acid-fast bacilli and polymerase chain reaction (PCR) assay testing (GeneXpert MTB/ RIF assay, Cepheid) for Mycobacterium tuberculosis from three different sputum samples were negative. Viral serologic testing was negative for HIV type-1/2. Axial (Fig 2) and coronal reconstruction (Fig 3) of the CT scan of the chest revealed a large, thick-walled cavitary lesion within consolidations in the left upper lobe with thickened pleura and bullous emphysema (Video 1).
Bronchoscopy showed an ubiquitous atrophic endobronchial mucous membrane without putrid secretion, but endobronchial lumen of the left upper lobe (segment 1/2) was obstructed by an irregular brown yellowish mass (Fig 4) . Bronchoalveolar lavage (BAL) revealed an increased total cell count of 18.0 Â 10 6 /100 mL BAL dominated by neutrophils (98%).
Hemacolor, Kinyoun, and Gram staining of BAL revealed no microscopic evidence for bacteria, acid-fast bacilli, or fungi. Bacterial cultures from BAL were negative; growths of Candida glabrata and mycobacterial culture results were pending. Galactomannan antigen testing from BAL fluid (BALF) was negative with an optical density index of 0.33 (optical density index cutoff of >1.0 for pulmonary aspergillosis in BALF). e14 Chest Imaging and Pathology for Clinicians
What is the diagnosis? 5, 6 Although the guidelines differ in some points, both recommend to establish CPA diagnosis made on the basis of the combination of characteristics including a CPA typical radiological pattern (see Radiological discussion), proof of mycological evidence, exclusion of alternative diagnosis, and chronic respiratory symptoms >3 months (or persistent radiological pattern >3 months). 1 To date, an increased Aspergillus IgG antibody titer seem to be the most promising parameter to prove mycological evidence with a sensitivity of up to 96% and a specificity of 98% depending on which assay is used. 7 Although this test is highly recommended, it has not been evaluated in a larger multicenter center study to date; therefore, direct comparison to proven CPA cases (histological detection or culture of Aspergillus species from lung tissue), which should be considered as reference standard, is missing. 8 An
Aspergillus IgG antibody assay was not performed in the patient, which may be symptomatic for the lack of awareness about the usefulness of this test for diagnosing CPA. In contrast, the galactomannan antibody test is well known from patients with invasive pulmonary aspergillosis (IPA), but the sensitivity and specificity from BALF in patients with CPA is inferior with 72% to 86% and 76% to 77%, respectively. 9, 10 This could be a plausible explanation for the false-negative test result in the patient. Also, the European Respiratory Society/ European Society for Clinical Microbiology and Infectious Diseases/European Confederation of Medical Mycology guideline just moderately recommends the use of galactomannan antigen test for the diagnosis of CPA (strength of recommendation B, quality of evidence II), but the data are based on a limited number of CPA patients and further studies are needed to prove this. 5 In addition, the routine microscopic evaluation of BAL was initially negative, as reported in our case presentation; therefore, we performed a second analysis of the stored BAL sample. This time, few fungal hyphae were detectable by careful evaluation of centrifuged Hemacolor-stained BAL cells (Fig 5) . The value of direct microscopy from respiratory samples in patients with CPA is unclear, although it has been suggested to be useful. 5 A study by Camuset and colleagues showed that only 6 of 24 patients with CPA had a positive direct microscopy from sputum bronchial aspiration or BALF. 11 In the patient, only a second and timeconsuming analyses of the centrifuged BAL cells revealed few fungal hyphae, assuming that the detection rate of hyphae in BAL might be limited by routine evaluation. Concentration of respiratory samples by centrifugation and fungal specific staining may increase the detection rate. 12 Management of patients with CPA needs a long-term commitment with a multimodal and personalized treatment approach. 13 Timely antifungal treatment can prevent progression to lung fibroses, control of respiratory symptoms, and improve life quality; however, antifungal treatment will not lead to relapsefree cure, and the mortality is still high with a five-year survival rate of about 40% to 60%. 14,15 A major difference of CPA compared with other chronic pulmonary infections is that CPA is still a fatal disease, even under antifungal treatment. In toto resection of a single/simple aspergilloma offers the only chance for relapse-free cure. First-line treatment with itraconazole or voriconazole is generally recommended for 6 months, respectively, despite large intrapatient variability and response to treatment (Table 1) . 5 Some patients may need lifelong treatment (if tolerated). Side effects are common, demanding close follow-ups and often limiting treatment continuation. For treatment and dosing optimization, therapeutic drug monitoring is recommended. 5 Development of triazole resistance to
Aspergillus species has to be considered and may be e16 Chest Imaging and Pathology for Clinicians A combination of different diagnostic methods seems reasonable; if possible, perform a bronchoscopy to obtain histology and BAL to perform additional diagnostic methods (e.g., Galactomannan, culture) to prove mycological evidence and to exclude alternative diagnoses. Isavuconazole is suggested to be effective, although evidence in CPA patients is lacking. It is recommended as third-line treatment (equivalent to posaconazole) by the UK National Aspergillosis Centre. May be considered in patients with severe disease at presentation or as "salvage" treatment, but there is limited evidence. 5, 22 chestjournal.org e17 associated with treatment failure. 16 Aspergillus culture from respiratory samples is still necessary to provide mycological resistance testing, even when CPA diagnosis has been established on the basis of indirect diagnostic methods. Biomarker guidance to individualize the duration of antifungal treatment is still lacking, and a treatment outcome definition with commonly accepted end points is not established so far. 8 
Radiologic Discussion
Chest imaging plays a central role for the diagnosis of CPA. Several radiological patterns are characteristic for CPA, including a single/simple aspergilloma, chronic cavitary pulmonary aspergillosis (CCPA), chronic fibrosing pulmonary aspergillosis (CFPA), aspergillus nodule(s), and subacute invasive aspergillosis (SAIA; formally called chronic necrotizing pulmonary aspergillosis or semi-invasive pulmonary aspergillosis) ( Table 1) . 5 The most frequent entity is CCPA. The radiological pattern in the patient refers most likely to CCPA with intracavitary/endobronchial fungal mass with considerable fibrosis and pleural thickening, which already suggests development to CFPA. Untreated, it may progress to CFPA, which is defined as lung fibrosis of at least two lobes. 5 Progression to lung fibroses leads to loss of lung function and life quality. Timely diagnosis of CPA is crucial to monitor progression and to start antifungal treatment. Although antifungal treatment will not lead to relapse-free cure, it can prevent or slow down further destruction of the lung.
The most prominent entity of CPA is the single/simple aspergilloma, which is defined as a fungal ball in a preformed cavity of the lung with upper lobe
predominance. An aspergilloma represents the latest stage of disease. At an earlier stage, Aspergillus species may grow along the inner wall of the cavity appearing on CT scan of the chest as a soft and undulating inner cavity wall with or without pleural thickening or mild accompanied infiltrates. All of these different CPA entities can overlap, and it is not always possible to differentiate. Lack of awareness of the variable radiological features is supposed to be one explanation for the underestimation of the disease in a real-life setting. A CT scan of the chest should be preferred. As demonstrated by the patient, the radiograph often shows no typical CPA findings and is definitely inferior to a CT scan, but might be the only option in resourceconstrained settings.
To date, chest imaging is the only objective parameter to evaluate antifungal treatment response. 17 Pleural and cavitary wall thickness are useful radiological parameters to assess treatment response. A decrease of pleural or cavitary wall thickness is usually associated with clinical improvement. 17 Of interesting, changes in the cavitary size do not to be a promising parameter to evaluate treatment response, but the evidence is limited. 17 Fungus balls may disappear during antifungal treatment; this may also be considered as treatment response. Any radiological deterioration such as increase of pleural and cavitary wall thickness, new nodule(s), or increase of lung fibroses should be carefully reevaluated with regard to antifungal resistance, inappropriate drug levels (eg, malabsorption, drug-drug interaction, patient compliance), and alternative diagnosis.
Pathologic Discussion
Biopsy of the endobronchial mass showed microscopic a network of fungal hyphae suspicious for Aspergillus species. The patient underwent resection of the left upper lobe demonstrating macroscopic multiple solid and cavitary lesions of up to 1.5 cm, which histologically revealed fibrotic lung tissue with a dense inflammatory infiltrate and disseminated fungal hyphae. Fibrotic tissue directly adjacent to lung tissue did not show hyphal invasion, and there was no invasion of bronchioles or vessels in the patient (Fig 6) .
These histologic findings correlate with the diagnosis of CCPA. As a distinguishing feature to invasive forms, Aspergillus species hyphae were only found within the cavities and not in surrounding lung tissue. 18 Localized bronchiectasis with cavity formation, chronic inflammation, and associated fibrosis appears to be the e18 Chest Imaging and Pathology for Clinicians histological hallmark of CCPA. 5, 19 Instead, fungal hyphae invading lung parenchyma resulting in a necrotic and acute inflammatory tissue response with microabscess formation and intra-alveolar hemorrhage correspond to the diagnosis of SAIA or IPA. 5, 20 Histopathological examination of lung tissue is the reference standard for the diagnosis of aspergillosis. It also allows exclusion of other diagnoses, such as malignancy or nonfungal infectious diseases. Here, resection of lesions allows definite distinction between SAIA and CCPA, which mostly does not apply for biopsy material. 5 The value of biopsies (transbronchial or percutaneous) for the diagnosis of IPA is in particular depending on biopsy depth. 21 According to a study by Denning and colleagues, bronchoscopic biopsy samples yielded negative findings in seven of eight patients with CCPA. 19 All biopsies showed chronic inflammation and fibrosis only. Especially in biopsies, the absence of hyphae does not exclude the diagnosis of CCPA because of the paucity of hyphae and sampling mistakes. In contrast, evidence of hyphae in respiratory samples (as in this case) alone is not sufficient for the diagnosis of CCPA, because of many other conditions yielding Aspergillus species into the airways. fungal hyphae (arrow) in H&E-stained tissue. D, Gomori-silver staining Â400. E, PAS staining Â400 showing fungal hyphae (*) surrounded by inflammatory cells.
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In addition to the histologic examination, DNA from formalin-fixed paraffin-embedded (FFPE) tissue was extracted using the Maxwell RSC instrument (Promega). For the detection of fungal species, extracted DNA was amplified and analyzed using the FUNGI 2.1 LCD-Array Kit and the corresponding primer mix (Chipron). This PCR assay targets internal transcribed spacer regions within the ribosomal DNA. The PCR product was identified to be Aspergillus versicolor/Aspergillus sydowi by hybridization. The DNA extracted from FFPE tissue was also used in a seminested PCR targeting the mitochondrial DNA of fungi belonging to the genus Aspergillus. Because of only small amounts obtained, sequencing did not provide more information. Identification of fungal elements from FFPE samples by molecular methods is limited by several issues. Treatment with formalin causes destruction of DNA (ie, PCR products of up to 500 base pairs can be amplified from FFPE tissue samples only). To detect all members within a family of molds but also to distinguish genera multicopy-conserved fungal genes such as ribosomal DNA are targeted. But the variability within the targets is not enough to distinguish species. Because of limited amounts of fungal DNA surrounded by human DNA, primers must be specific enough to amplify fungal DNA only; however, microscopy of hyphae is rarely able to distinguish fungal orders. In this case, PCR identified the hyphae seen by histopathology to belong to the genus Aspergillus.
Conclusions
CPA is a severe fungal infection usually found in immunocompetent patients with underlying structural respiratory disorders. To establish the diagnoses of CPA is challenging, which is attributed to three main aspects.
First, general and respiratory symptoms are not specific and may overlap with symptoms caused by the underlying respiratory disorder. Second, the radiological pattern of CPA is variable, and physicians have to be aware of the different CPA entities to raise suspicion and to initiate further diagnostic steps. Third, the quality of different mycological tests is uncertain because of a lack of evidence and the proof that mycological evidence should always be based on a combination of different testes. Histopathological examination of lung tissue is considered to be the diagnostic reference standard, but often only lung tissue resection and not biopsy material of lesions allow definite evaluation.
Once the diagnosis is established, patient care needs a long-term commitment and often a multimodal approach, including surgery and antifungal treatment. To date, diagnosis and management of CPA is unsatisfying. Activities should aim to advance patient care from programmatic management to personalized medicine by improving individual risk assessments for disease development, design of tailor-made therapies, therapeutic drug monitoring, and biomarker-oriented treatment guidance to individualize the duration of therapies. 13 
